Lupin Limited
LUPIN
株式のランク
#2107
Lupin Limited is a pharmaceutical firm dedicated to the creation,... Lupin Limited is a pharmaceutical firm dedicated to the creation, manufacturing, commercialization, and distribution of a wide array of branded and generic medications, biotechnology items, and active pharmaceutical ingredients (APIs). Its comprehensive product portfolio addresses diverse therapeutic categories, including cardiovascular health, diabetes management, asthma, pediatric care, central nervous system disorders, gastrointestinal issues, anti-infectives, nonsteroidal anti-inflammatory drug (NSAID) therapy, respiratory ailments, women's health, and anti-tuberculosis treatments. Beyond its primary offerings, Lupin also supplies biosimilars and over-the-counter (OTC) medicines, alongside specialized pharmaceutical products. The company actively pursues drug discovery and development initiatives focused on oncology, immunology, and metabolic disorders, complementing these efforts with bio-clinical research. Lupin Limited maintains an extensive operational network comprising 18 laboratories, 280 LupiMitra collection centers, and 450 pick-up points. Its global presence extends across numerous countries, such as India, the United States, the United Kingdom, South Africa, Australia, the Philippines, Germany, the Netherlands, Mexico, and Brazil. Originally named Lupin Chemicals Limited, the company adopted its current identity, Lupin Limited, in 2001 following its merger with Lupin Laboratories Limited. Established in 1968, Lupin Limited is based in Mumbai, India.
株価
$21.43
時価総額
$9.80B
変化（1日）
0.14%
変化（1年）
-2.88%
国
IN
取引 Lupin Limited (LUPIN)
カテゴリー
Healthcare
Lupin Limited（LUPIN）の利益
Jun 2026 時点の利益 TTM: $824.86M
Lupin Limited の最新の財務報告によると、同社の現在の利益は $824.86M です。2024 年には $290.50M の利益を上げ、これは 2023 年の利益 $87.18M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Lupin Limited の利益の推移（2004 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $824.86M | 75.71% |
| 2025 | $469.45M | 61.60% |
| 2024 | $290.50M | 233.20% |
| 2023 | $87.18M | -148.23% |
| 2022 | $-180.77M | -178.93% |
| 2021 | $229.01M | 127.84% |
| 2020 | $100.52M | -50.46% |
| 2019 | $202.90M | 141.60% |
| 2018 | $83.98M | -84.63% |
| 2017 | $546.37M | 8.74% |
| 2016 | $502.47M | -8.18% |
| 2015 | $547.26M | -3.94% |
| 2014 | $569.71M | 60.84% |
| 2013 | $354.21M | 50.17% |
| 2012 | $235.88M | 5.71% |
| 2011 | $223.13M | 19.92% |
| 2010 | $186.07M | 55.87% |
| 2009 | $119.38M | -11.57% |
| 2008 | $135.00M | 43.62% |
| 2007 | $93.99M | 85.65% |
| 2006 | $50.63M | 132.81% |
| 2005 | $21.75M | -50.60% |
| 2004 | $44.02M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $1.76B | 113.92% |
IN
|
